Literature DB >> 1084367

C1q (c1) receptor on human platelets: inhibition of collagen-induced platelet aggregation by C1q (C1) molecules.

E A Suba, G Csako.   

Abstract

Hemolytically active human C1q incubated with EA before the addition of complement inhibited the immune hemolysis. On the contrary, heat-inactivated preparation (30 min 56 degrees C) was ineffective. Preincubation of EA with bovine collagen also resulted in a decreased hemolysis. When aggregation was measured by a turbidimetric method in citrated human platelet-rich plasma, it was found that hemolytically active human C1q (C1) alone does not induce platelet aggregation. However, in its presence the platelets failed to aggregate or exhibited a significantly reduced aggregation response to bovine collagen. The inhibition by C1q depended on the preincubation time with platelets. Heat treatment (30 min 56 degrees C) destroyed the inhibitory action of C1q (C1). The effect of C1q proved to be highly specific because different C1q preparations at their inhibitory doses in collagen-induced platelet aggregation did not influence the response to other aggregating agents (bovine thrombin, ADP, horse anti-human thymocyte globulin, goat anti-baboon platelet antiserum). The results prove that collagen and C1q are capable of binding to the same site(s); namely, to those of EA and human platelets; furthermore, they suggest the presence of a receptor for C1q (C1) on human platelets.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1084367

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

Review 1.  The chemistry and biology of complement receptors.

Authors:  R D Schreiber
Journal:  Springer Semin Immunopathol       Date:  1984

Review 2.  Relationships among the complement, kinin, coagulation, and fibrinolytic systems.

Authors:  J S Sundsmo; D S Fair
Journal:  Springer Semin Immunopathol       Date:  1983

3.  Immunochemical quantitation of complement components of Clq and C3 in sera and synovial fluids of patients with bone and joint diseases.

Authors:  T Ochi; K Yonemasu; K Ono
Journal:  Ann Rheum Dis       Date:  1980-06       Impact factor: 19.103

4.  Inhibition of the activation of Hageman factor (factor XII) by complement subcomponent C1q.

Authors:  E H Rehmus; B M Greene; B A Everson; O D Ratnoff
Journal:  J Clin Invest       Date:  1987-08       Impact factor: 14.808

5.  Binding of soluble immune complexes to Raji lymphocytes. Role of receptors for complement components, C1q and C3-C3b.

Authors:  R C Gupta; F C McDuffie; G Tappeiner; R E Jordon
Journal:  Immunology       Date:  1978-04       Impact factor: 7.397

6.  Identification of the Raji cell membrane-derived C1q inhibitor as a receptor for human C1q. Purification and immunochemical characterization.

Authors:  B Ghebrehiwet; L Silvestri; C McDevitt
Journal:  J Exp Med       Date:  1984-11-01       Impact factor: 14.307

7.  Similarities and dissimilarities between the binding ability of C1q and collagen.

Authors:  G Csákó; E A Suba; A Herp
Journal:  Clin Exp Immunol       Date:  1981-04       Impact factor: 4.330

8.  Pathopysiological aspects of immune complex diseases. Part II. Phagocytosis, exocytosis, and pathogenic depositions.

Authors:  H H Sedlacek
Journal:  Klin Wochenschr       Date:  1980-06-16

9.  Activation of human platelets by antibodies to thymocytes and beta 2-microglobulin. I. Qualitative and quantitative aspects of the platelet aggregation induced by HATG and SA beta 2mG.

Authors:  G Csákó; E A Suba; R Wistar
Journal:  Clin Exp Immunol       Date:  1980-02       Impact factor: 4.330

10.  Platelet-associated DNA and anti-DNA antibody in systemic lupus erythematosus with nephritis.

Authors:  G Frampton; S Perl; A Bennett; J S Cameron
Journal:  Clin Exp Immunol       Date:  1986-03       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.